NovaBay Pharmaceuticals, Inc. (NASDAQ:NBY) dropped 7.8% on Tuesday . The stock traded as low as $0.55 and last traded at $0.57, approximately 254,201 shares were traded during mid-day trading. A decline of 78% from the average daily volume of 1,165,195 shares. The stock had previously closed at $0.62.
The company has a fifty day moving average price of $1.08 and a two-hundred day moving average price of $1.15.
About NovaBay Pharmaceuticals (NASDAQ:NBY)
NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.
Read More: Do Tariffs Work?
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.